Your browser is no longer supported. Please, upgrade your browser.
Settings
PTLA Portola Pharmaceuticals, Inc. daily Stock Chart
PTLA [NASD]
Portola Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.55 Insider Own0.50% Shs Outstand76.55M Perf Week-8.58%
Market Cap2.13B Forward P/E- EPS next Y-2.87 Insider Trans-11.65% Shs Float67.24M Perf Month6.80%
Income-304.20M PEG- EPS next Q-0.91 Inst Own- Short Float23.32% Perf Quarter-8.67%
Sales80.10M P/S26.57 EPS this Y-10.30% Inst Trans2.27% Short Ratio13.85 Perf Half Y-10.47%
Book/sh0.01 P/B2780.00 EPS next Y21.60% ROA-76.00% Target Price42.00 Perf Year5.70%
Cash/sh3.58 P/C7.77 EPS next 5Y- ROE-403.10% 52W Range14.81 - 37.95 Perf YTD42.42%
Dividend- P/FCF- EPS past 5Y-7.80% ROI- 52W High-26.75% Beta2.00
Dividend %- Quick Ratio3.60 Sales past 5Y30.70% Gross Margin68.90% 52W Low87.71% ATR1.33
Employees324 Current Ratio3.60 Sales Q/Q610.00% Oper. Margin- RSI (14)47.49 Volatility3.93% 5.29%
OptionableYes Debt/Eq464.67 EPS Q/Q39.70% Profit Margin- Rel Volume1.09 Prev Close28.81
ShortableYes LT Debt/Eq432.00 EarningsAug 07 AMC Payout- Avg Volume1.13M Price27.80
Recom1.80 SMA20-1.68% SMA502.08% SMA2000.83% Volume1,233,955 Change-3.51%
Aug-05-19Resumed Credit Suisse Neutral $35
Jul-10-19Resumed Credit Suisse Neutral
Aug-27-18Upgrade Credit Suisse Underperform → Neutral
Aug-10-18Downgrade Credit Suisse Neutral → Underperform
Mar-01-18Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-01-17Initiated Goldman Buy $75
Aug-24-17Upgrade Credit Suisse Neutral → Outperform
Jun-26-17Reiterated Morgan Stanley Overweight $50 → $70
Jun-26-17Reiterated Citigroup Buy $51 → $78
Feb-24-17Upgrade Oppenheimer Perform → Outperform
Jan-03-17Upgrade Citigroup Neutral → Buy
Dec-27-16Reiterated Credit Suisse Outperform $20 → $29
Aug-19-16Downgrade Citigroup Buy → Neutral
May-31-16Downgrade Credit Suisse Outperform → Neutral $33 → $30
Mar-28-16Reiterated Credit Suisse Outperform $47 → $34
Mar-28-16Downgrade Goldman Buy → Neutral $65 → $30
Dec-18-15Initiated Goldman Buy
Aug-22-19 08:30AM  Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences PR Newswire
Aug-19-19 04:33PM  Edited Transcript of PTLA earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-16-19 11:08AM  Here's Why Portola Pharmaceuticals (NASDAQ:PTLA) Can Afford Some Debt Simply Wall St.
Aug-13-19 07:32PM  Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire
07:25AM  The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results Benzinga
Aug-12-19 04:43PM  Portola Pharmaceuticals Announces Proposed Offering of Common Stock PR Newswire
Aug-08-19 04:15PM  Why Portola Pharmaceuticals Is Rocketing 10.9% Higher Today Motley Fool +11.86%
Aug-07-19 09:24PM  Portola Pharmaceuticals Inc (PTLA) Q2 2019 Earnings Call Transcript Motley Fool
06:25PM  Portola Pharmaceuticals (PTLA) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update PR Newswire
11:20AM  Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View Zacks
11:15AM  Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y Zacks
08:42AM  Zoetis (ZTS) Looks Good: Stock Adds 7.6% in Session Zacks
Aug-06-19 10:51AM  Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance Zacks
08:30AM  Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in Europe PR Newswire
Aug-05-19 07:00AM  U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa PR Newswire
Jul-31-19 10:36AM  Portola Pharmaceuticals (PTLA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-17-19 08:30AM  Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019 PR Newswire
Jul-08-19 08:30AM  Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa Inhibitors PR Newswire
Jun-19-19 11:05AM  Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma PR Newswire
May-28-19 04:30PM  Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences GlobeNewswire
May-22-19 10:45AM  Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Spontaneous (Non-Traumatic) Intracranial Hemorrhage GlobeNewswire
May-17-19 07:20PM  Edited Transcript of PTLA earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-09-19 08:16AM  3 Key Takeaways From Portola Pharmaceuticals' Quarterly Results Motley Fool
May-08-19 02:23PM  Portola Pharmaceuticals Inc (PTLA) Q1 2019 Earnings Call Transcript Motley Fool -8.82%
01:10PM  Why Portola Pharmaceuticals Is Tumbling 14.5% Today Motley Fool
09:25AM  Portola Pharmaceuticals (PTLA) Reports Q1 Loss, Tops Revenue Estimates Zacks
08:19AM  Portola Pharmaceuticals: 1Q Earnings Snapshot Associated Press
08:01AM  Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
06:30AM  Portola Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-02-19 02:39PM  Did Hedge Funds Drop The Ball On Portola Pharmaceuticals Inc (PTLA)? Insider Monkey
May-01-19 10:32AM  Portola Pharmaceuticals (PTLA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Apr-26-19 02:00PM  European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals Ondexxya (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors GlobeNewswire
Apr-24-19 08:30AM  Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Development GlobeNewswire
Apr-17-19 04:15PM  Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019 GlobeNewswire
Apr-12-19 12:01PM  Portola Pharmaceuticals: Is It Still a Buy? Motley Fool
Mar-26-19 05:32PM  Amid talk of buyout, Peninsula biotech zeroes in on its blood-thinner antidote American City Business Journals
Mar-25-19 09:19AM  Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more American City Business Journals
Mar-21-19 06:30AM  HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results CNW Group
Mar-20-19 05:00PM  Portola Pharmaceuticals Co-Founder Dr. Charles Homcy Retires from the Companys Board of Directors GlobeNewswire
Mar-07-19 12:46PM  Edited Transcript of PTLA earnings conference call or presentation 1-Mar-19 1:30pm GMT Thomson Reuters StreetEvents
Mar-06-19 04:10PM  Portola Pharmaceuticals to Webcast Presentation at Cowen and Companys 39th Annual Health Care Conference GlobeNewswire
Mar-01-19 01:57PM  Portola Pharmaceuticals Inc (PTLA) Q4 2018 Earnings Conference Call Transcript Motley Fool +13.06%
12:45PM  Why Portola Pharmaceuticals Skyrocketed 15.3% Today Motley Fool
07:38AM  European CHMP Adopts Positive Opinion on Ondexxya (andexanet alfa) Portola Pharmaceuticals Factor Xa Inhibitor Reversal Agent GlobeNewswire
Feb-28-19 09:28AM  Aiming at genetic diseases, Peninsula stealth biotech emerges with $191 million American City Business Journals
Feb-22-19 10:30AM  Will Portola Pharmaceuticals (PTLA) Report Negative Earnings Next Week? What You Should Know Zacks
Feb-19-19 08:25AM  Report: Exploring Fundamental Drivers Behind Crocs, Portola Pharmaceuticals, ANSYS, Alpha and Omega Semiconductor, PetMed Express, and MYOS RENS Technology New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-07-19 04:03PM  Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding GlobeNewswire
Feb-01-19 11:45AM  Is There An Opportunity With Portola Pharmaceuticals, Inc.s (NASDAQ:PTLA) 22.17% Undervaluation? Simply Wall St.
08:30AM  Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on Friday, March 1, 2019 GlobeNewswire
Jan-30-19 08:43AM  Portola Pharmaceuticals to Present Full Results from the ANNEXA-4 Study of Andexxa During a Late-Breaking Oral Presentation at the International Stroke Conference 2019 GlobeNewswire
Jan-28-19 09:23AM  Portola Pharmaceuticals Appoints Sheldon Koenig as Chief Commercial Officer GlobeNewswire
Jan-03-19 02:01PM  Take Profits on This Pharma Stock Schaeffer's Investment Research
Jan-02-19 09:25AM  Portola Up as Large-Scale Andexxa Production Gets FDA Nod Zacks
Dec-31-18 03:59PM  Portola stock shoots higher after FDA approval MarketWatch +14.22%
03:19PM  U.S. Food and Drug Administration Approves Portola Pharmaceuticals Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process GlobeNewswire
Dec-18-18 08:30AM  Portola Pharmaceuticals to Webcast Corporate Update on January 8, 2019 GlobeNewswire
Dec-17-18 02:58PM  Portola Pharmaceuticals, Inc. (NASDAQ:PTLA): Is Breakeven Near? Simply Wall St.
Dec-13-18 04:45PM  Here's Why Portola Pharmaceuticals Fell 11% Today Motley Fool -11.40%
12:07AM  Is Portola Pharmaceuticals Inc (PTLA) A Good Stock To Buy? Insider Monkey
Dec-12-18 10:15AM  Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya Zacks +10.62%
Dec-11-18 11:13AM  Portola Pharma shares slide 6% on news of delay in EU review of treatment for bleeding MarketWatch -6.65%
07:00AM  CHMP Extends Review Period for Portola Pharmaceuticals Ondexxya (andexanet alfa) GlobeNewswire
Dec-04-18 07:30AM  Recent Analysis Shows Portola Pharmaceuticals, Xenia Hotels & Resorts, WestRock, Newtek Business Services, The ExOne, and VMware Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire -5.71%
Dec-03-18 09:15PM  Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies GlobeNewswire
Nov-09-18 09:16AM  Here's What Portola Pharmaceuticals Is Saying About Its Future Motley Fool -5.14%
Nov-08-18 07:05AM  Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and Global Blood Therapeutics ACCESSWIRE +21.41%
Nov-07-18 11:31PM  Edited Transcript of PTLA earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
07:30PM  Portola Pharmaceuticals (PTLA) Reports Q3 Loss, Tops Revenue Estimates Zacks
06:26PM  Portola Pharmaceuticals: 3Q Earnings Snapshot Associated Press
04:05PM  Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-06-18 04:30PM  Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences GlobeNewswire -5.12%
Nov-01-18 05:30PM  Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +5.64%
04:03PM  Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Oct-25-18 08:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Portola Pharmaceuticals, Cable One, Marriot Vacations Worldwide, United Technologies, Park-Ohio, and BioScrip New Research Emphasizes Economic Growth GlobeNewswire
Oct-23-18 08:30AM  Portola Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018 GlobeNewswire
Oct-11-18 03:36PM  Why Portola Pharmaceuticals Stock Shed 11% in September Motley Fool
Oct-09-18 03:44PM  What You Must Know About Portola Pharmaceuticals Incs (NASDAQ:PTLA) Market Risks Simply Wall St.
09:05AM  Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growing Health Crisis GlobeNewswire
Sep-26-18 11:14AM  Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status Zacks
Sep-25-18 04:38PM  Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Cerdulatinib, an Oral Syk/JAK Inhibitor for the Treatment of Peripheral T-Cell Lymphoma GlobeNewswire
Sep-24-18 11:10AM  Health Care Digest: Genentech's neuro legacy, uBiome's haul, plus saving moms American City Business Journals
Sep-20-18 08:30AM  Portola Pharmaceuticals Names Scott Garland President and Chief Executive Officer GlobeNewswire
Sep-12-18 08:26AM  The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt Benzinga
Sep-11-18 06:06PM  U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process GlobeNewswire
02:07PM  Here's Why Portola Pharmaceuticals, Inc. Fell 16.6% in August Motley Fool
Sep-07-18 08:30AM  Portola Pharmaceuticals Announces Executive Leadership Change GlobeNewswire
08:18AM  3 Top Biotech Stocks to Buy in September Motley Fool
Sep-05-18 06:15PM  Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:30AM  Market Trends Toward New Normal in Shutterstock, CrossAmerica Partners LP, Allegiance Bancshares, Portola Pharmaceuticals, StoneMor Partners, and Catalyst Biosciences Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Aug-31-18 08:30AM  Portola Pharmaceuticals Submits Prior Approval Supplement to U.S. FDA for Large-Scale Generation 2 Andexxa Process GlobeNewswire +5.51%
Aug-30-18 08:00AM  Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences GlobeNewswire
Aug-29-18 07:30AM  [$$] Portola Pharmaceuticals Director Scores With Stock Purchase Barrons.com
Aug-27-18 10:31AM  Sympathy Move: Portola Upgraded After Competitor Reports Sour Data Benzinga
09:56AM  Portola Pharmaceuticals (PTLA) Jumps: Stock Rises 9.1% Zacks
08:00AM  Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and AVEO Pharmaceuticals ACCESSWIRE
Aug-25-18 06:01PM  Insider Buys Of The Week: Andeavor, Corcept, Portola Benzinga
Aug-16-18 08:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within BioScrip, Powell Industries, Portola Pharmaceuticals, Daktronics, Cable One, and Park-Ohio New Research Emphasizes Economic Growth GlobeNewswire
Aug-10-18 05:45PM  Edited Transcript of PTLA earnings conference call or presentation 9-Aug-18 12:30pm GMT Thomson Reuters StreetEvents -5.39%
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RENTON HOLLINGSDirectorAug 08Option Exercise9.005,00045,00018,194Aug 09 06:51 PM
RENTON HOLLINGSDirectorAug 08Sale30.005,000150,00013,194Aug 09 06:51 PM
RENTON HOLLINGSDirectorApr 15Option Exercise9.005,00045,00014,000Apr 16 07:44 PM
RENTON HOLLINGSDirectorApr 15Sale34.455,000172,2509,000Apr 16 07:44 PM
Dier MardiEVP, CFO & CBOApr 04Sale37.3940,4861,513,82466,733Apr 08 07:03 PM
Wolff Henry WardDirectorMar 12Option Exercise5.105,00025,50015,766Mar 14 09:17 PM
HOMCY CHARLES JDirectorJan 02Option Exercise5.1045,923234,207165,403Jan 04 05:46 PM
HOMCY CHARLES JDirectorDec 19Option Exercise4.1025,782105,706119,480Dec 19 07:07 PM
HOMCY CHARLES JDirectorDec 17Option Exercise4.1064,218263,294176,689Dec 19 07:07 PM
HOMCY CHARLES JDirectorDec 17Sale18.6164,2181,195,002112,471Dec 19 07:07 PM
HOMCY CHARLES JDirectorNov 14Option Exercise4.1093,698384,16293,698Nov 16 05:24 PM
Curnutte John TInterim Co-President & EVP R&DAug 31Option Exercise0.0017,5000110,084Sep 05 06:43 PM
Dier MardiInterim Co-President & CFOAug 31Option Exercise0.0017,5000107,684Sep 05 07:27 PM
Fu TaoEVP, CBOAug 31Option Exercise0.0020,000087,196Sep 05 07:18 PM